Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jounce Therapeutics (JNCE)
NASDAQ:JNCE
Holding JNCE?
Track your performance easily
JNCE Stock Chart & Stats
Day’s Range$1.88 - $1.93
52-Week Range― - ―
Previous Close$1.93
Volume11.60M
Average Volume (3M)N/A
Market Cap
$98.95M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,140,277
10 Day Avg. Volume870,956
30 Day Avg. Volume2,105,980
Standard Deviation0.27
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)1.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Jounce Therapeutics News
PremiumMarket News
Buyout Offer Sends Jounce Jumping 20%
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNCE FAQ
What was Jounce Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Jounce Therapeutics’s market cap?
Currently, no data Available
When is Jounce Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jounce Therapeutics’s earnings last quarter?
Currently, no data Available
Is Jounce Therapeutics overvalued?
According to Wall Street analysts Jounce Therapeutics’s price is currently Overvalued.
Does Jounce Therapeutics pay dividends?
Jounce Therapeutics does not currently pay dividends.
What is Jounce Therapeutics’s EPS estimate?
Jounce Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jounce Therapeutics have?
Currently, no data Available
What happened to Jounce Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jounce Therapeutics?
Among the largest hedge funds holding Jounce Therapeutics’s share is Omega Fund Management, LLC. It holds Jounce Therapeutics’s shares valued at 510K.
---
Jounce Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
---
JNCE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---